Search | Invivogen

Human CD70 Antibody - Vorsetuzumab IgG1fut Isotype

Human IgG1, afucosylated

Binding of Anti-hCD70-hIgG1fut mAb to hCD70

Comparison of ADCC induction of Anti-hCD70 mAbs

Human CD70 Antibody - Vorsetuzumab Biosimilar

Human IgG1 - CAS #1165741-01-4

Comparison of ADCC induction of Anti-hCD70 mAbs

Binding of Anti-hCD70-hIgG1 mAb to hCD70

Human IFNAR Antibody - Anifrolumab Biosimilar

Human IgG1 Fc silent - CAS #1326232-46-5

Dose-dependent inhibition of IFN-α and IFN-β signaling in HEK-Blue™ IFN-α/β cells using Anifrolumab

Recombinant human IL-7 protein - Bioactive cytokine

Recombinant cytokine, CHO cells

Detection by SDS-PAGE

Dose-response in HEK-Blue™ IL-7 cells to recombinant IL-7 cytokine

Recombinant human IL-1β protein - Bioactive cytokine

Recombinant cytokine, source: CHO cells

Detection by SDS-PAGE of CHO-derived IL-1β

Dose-response in HEK-Blue™ IL-1β cells to recombinant IL-1β cytokines

Neutralization of hIL-1β signaling using Nidanilimab

Human CD70 Antibody - Vorsetuzumab IgG1NQ Isotype

Human IgG1, Fc silent

Comparison of ADCC induction of Anti-hCD70 mAbs

Binding of Anti-hCD70-hIgG1NQ mAb to hCD70

Human VISTA Antibody - Onvatilimab IgG1NQ Isotype

Human IgG1, Fc silent

Binding of Anti-hVISTA-hIgG1 to target cells

ADCC potency of native and engineered Anti-hVISTA isotype family

ADCC assay with Raji-hVISTA cells

Mouse PD-L1 Antibodies (clones 10F.9G2 and RG7446)

Mouse IgG1 (D265A) Fc silent - For in vitro and in vivo use

Binding specificity to recombinant mouse or human PD-L1

Validation of Anti-PD-L1 InvivoFit™ mAbs by flow cytometry

E. coli β-Gal x Human CD3 Bispecific Antibody - Negative Control

Control scFv antibody - Recombinant

Activation of Jurkat-Lucia™ NFAT cells with Anti-hCD19-CD3

Anti-βgal-hCD3 does not allow Jurkat-Lucia™ NFAT cell activation

Human CD19 x E. coli β-Gal Bispecific Antibody - Negative control

Control scFv antibody - Recombinant

Activation of Jurkat-Lucia™ NFAT cells with Anti-hCD19-CD3

Absence of Jurkat-Lucia™ NFAT cell activation using Anti-βgal-hCD3

Human CD19 x Human CD3 Bispecific Antibody

Blinatumomab scFv antibody - Recombinant

Evaluation of T cell activation

Target specificity of Anti-hCD19-CD3

Jurkat-Lucia™ NFAT cell activation

Activation of Jurkat-Lucia™ NFAT cells with Anti-hCD19-CD3

Recombinant human IFN-α2b protein - Bioactive cytokine

Recombinant cytokine, source: CHO cells

Human IFN-α2b SDS-PAGE analysis

Dose-response of HEK-Blue™ IFN-α/β cells to recombinant human IFN-α2b

Neutralization of cellular response to IFN-α using Anifrolumab biosimilar

Dose-dependent inhibition of HEK-Blue™ IFN-α/β cell response using Rontalizumab

Human EGFR Antibody - Cetuximab IgG2 Isotype

Human IgG2

Default product image

Anti-hPD1-Pem-hIgG1NQ

Human PD-1 (pembrolizumab) antibody - Human IgG1, non-glycosylated

Default product image

Human TIGIT Antibody - Etiligimab IgG1fut Isotype

Human IgG1, afucosylated

Binding of Anti-hTIGIT-hIgG1fut to target cells

Comparison of ADCC potency for native and engineered anti-human TIGIT antibody isotypes

Human CD27 Antibody - Varlilumab IgG1fut Isotype

Human IgG1, afucosylated

Characteristics and mechanism of Anti-hCD27 biosimilar isotype family

Comparison of ADCC induction of Anti-hCD27 mAbs

Binding of Anti-hCD27-hIgG1fut mAb to hCD27

Human CD3 x Human CD28 Antibody For T Cell Activation & Expansion

T cell activating and expanding bispecific antibody anti-CD3 & anti-CD28

Activated morphology of human T Cells

Human T cell expansion

CD25 & CD69 cell surface staining after T cell activation

Human RANKL (CD254) Antibody - Denosumab biosimilar

Human IgG2 - CAS #615258-40-7

Neutralization of cellular response to RANKL using Denosumab biosimilar

Validation of Anti-hRANKL-hIgG2 mAb by ELISA

Human RANKL (CD254) Antibody - Denosumab IgG1 Isotype

Human IgG1

Validation of Anti-hRANKL-hIgG1 mAb by ELISA

Human CD20 Antibody - Ofatumumab IgG4 (S228P) isotype

Human IgG4 (S228P)

Default product image